Validation of the 2022 Clinical Diagnostic Criteria of Familial Hypercholesterolemia in Japan
Journal of Atherosclerosis and Thrombosis · 2024
DOI: 10.5551/jat.64549 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Atherosclerosis and Thrombosis, 2024. Verfasst von Hayato Tada und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kanazawa University. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kanazawa University.
- Department of Clinical Genetics, Ishikawa Prefectural Central Hospital.
- Department of Internal Medicine, Kaga Medical Center.
Zitieren
APA
Tada, H., Nohara, A., Usui, S., Sakata, K., Kawashiri, M. A., & Takamura, M. (2024). Validation of the 2022 Clinical Diagnostic Criteria of Familial Hypercholesterolemia in Japan. Journal of Atherosclerosis and Thrombosis. https://doi.org/10.5551/jat.64549
Vancouver
Tada H, Nohara A, Usui S, Sakata K, Kawashiri MA, Takamura M. Validation of the 2022 Clinical Diagnostic Criteria of Familial Hypercholesterolemia in Japan. Journal of Atherosclerosis and Thrombosis. 2024. doi:10.5551/jat.64549
BibTeX
@article{Tada2024,
author = {Tada, Hayato and Nohara, Atsushi and Usui, Soichiro and Sakata, Kenji and Kawashiri, Masa-Aki and Takamura, Masayuki},
title = {Validation of the 2022 Clinical Diagnostic Criteria of Familial Hypercholesterolemia in Japan},
journal = {Journal of Atherosclerosis and Thrombosis},
year = {2024},
doi = {10.5551/jat.64549}
}
EUVIMED